Cargando…
Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021
SIMPLE SUMMARY: Triple negative breast cancer (TNBC) represents 15 to 20% of all breast cancers in the United States. The main treatment option remains chemotherapy, despite limited efficacy. New biologic and targeted agents are increasingly emerging for the treatment of TNBC. Given the continuous a...
Autores principales: | Bou Zerdan, Maroun, Ghorayeb, Tala, Saliba, Fares, Allam, Sabine, Bou Zerdan, Morgan, Yaghi, Marita, Bilani, Nadeem, Jaafar, Rola, Nahleh, Zeina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909187/ https://www.ncbi.nlm.nih.gov/pubmed/35267561 http://dx.doi.org/10.3390/cancers14051253 |
Ejemplares similares
-
Metabolic Syndrome: Updates on Pathophysiology and Management in 2021
por: Fahed, Gracia, et al.
Publicado: (2022) -
Carbapenemase Inhibitors: Updates on Developments in 2021
por: Bou Zerdan, Maroun, et al.
Publicado: (2022) -
Management of HR+/HER2+ lobular breast cancer and trends do not mirror better outcomes
por: Yaghi, Marita, et al.
Publicado: (2022) -
Single Cell RNA Sequencing: A New Frontier in Pancreatic Ductal Adenocarcinoma
por: Bou Zerdan, Maroun, et al.
Publicado: (2022) -
Multidisciplinary supportive care in systemic light chain amyloidosis
por: Maroun, Bou Zerdan, et al.
Publicado: (2022)